Skip to main content
. 2016 Sep 29;8(11):805–814. doi: 10.14740/jocmr2741w

Table 4. Treatment-Emergent Adverse Events.

Insulin (n = 15) Insulin + tofogliflozin (n = 19) Glargine + tofogliflozin (n = 19)
Hypoglycemia (n) 4 5 4

*Patient self-reporting only. Number of patients with hypoglycemia during the follow-up period. There were no significant differences among the groups.